"I would consider when sleeping to keep one eye open on Multiple Sclerosis"
I totally agree. We're even now have statistically significant mean reduction in Thrombospondin-1 (-49%), and increases in LTBP4 (20.7%), soluble
CXCL16 (29.9%), and VCAM-1 (18.0%) compared to baseline levels (FDR p-value <0.0005) to support ATL1102 in DMD ..
As Mark Diamond once said, "If we show good activity in DMD that could be highly supportive of an MS study." I believe the company will pursue further in this area when the time comes.
Anp at world muscle society, page-36
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
